We’re pleased to announce that CreateIP partners, Robert Snoep and Rachel Colley, have been recognised as amongst the world’s leading IP professionals 2017 in two of the world’s leading IP guides – the IAM Patent 1000 and WIPR Leaders.
CreateIP founder, Robert Snoep, was named in the Intellectual Asset Management­ IAM Patent 1000 as one of the top patent specialists in the world. It is universally acknowledged as the definitive guide to leading patent lawyers, attorneys and firms in over 40 jurisdictions.

IAM’s recognition reads: “In operation since 2009, CreateIP is a refreshing option for clients and a firm that challenges conventional […]

We’re delighted that, for the fourth year in a row, we have made the finals of the New Zealand Law Awards in the Intellectual Property Specialist Law Firm of the Year category.

The winners will be announced at the 12th annual New Zealand Law Awards on Thursday 17 November at The Langham hotel in Auckland.

We wish all the very best of luck to all the finalists.

Rachel Colley of CreateIP shares four key strategies that a company wishing to access the China market can implement to best protect itself, and pre-empt IP issues.

 
2015 has seen the influence and importance of China continue to increase, and the case for having a presence in the Chinese market grows more compelling every day. Yet entry into China still scares a number of international companies. IP theft is perceived as being rife and doubts as to fair treatment in the country’s legal systems are some of the barriers to foreign companies.
 
However, China is on track to transition from a nation […]

CreateIP is delighted to announce that for the third year running, it is a finalist in the ‘Intellectual Property Specialist Law Firm Of The Year’ award at the 2015 New Zealand Law Awards. The winner will be announced at the awards ceremony taking place in Auckland on 17 November 2015. Fingers crossed and watch this space!

D’Arcy v Myriad Genetics Inc & Anor: Australian High Court rules that isolated genetic material is not patentable subject matter.

In a reversal of the previous decision of the Federal Court of Australia, the High Court of Australia (highest Australian court) ruled on 7 October 2015 that isolated genetic material coding for a polypeptide (in the form of DNA or RNA) is not patentable subject matter (http://www.hcourt.gov.au/cases/case_s28-2015).

The judgment held that an isolated nucleic acid coding for the BRCA1 protein with specific variations indicative of breast and ovarian cancer (as claimed in claims 1-3 of Australian Patent No. 686004) does not fall […]